AGENT-797 in Patients With Relapsed/Refractory Multiple Myeloma

What's the purpose of this trial?

This is a Phase I, open-label, dose-escalation, single arm study to explore the safety, tolerability, and preliminary clinical activity of agenT-797, an unmodified, allogeneic iNKT cell therapy, in subjects with relapsed/refractory MM, as well as define the RP2D.

This is an upcoming trial that has not yet started accepting patients.


Additional Trial Information

Phase 1

Enrollment: 30 patients (estimated)

View More

You may be able to join this trial if you:

The following criteria is a partial list of reasons why patients may be eligible to participate in this clinical trial. Further evaluation with a medical professional is required. Create your account or call us today for help (888) 828-2206.

Inclusion Criteria:

  • Written informed consent obtained prior to any screening procedures and in accordance with federal, local, and institutional guidelines.
  • Age ≥ 18 years.
  • Confirmed diagnosis, and evidence of progressive disease or clinical relapse as defined by International Myeloma Working Group (IMWG) criteria and following prior therapy for MM:
    1. Relapsed or refractory MM requiring current treatment.
    2. Previously failed ≥ 3 prior regimens.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 1.
  • Estimated life expectancy ≥ 4 months.
  • No other medical, surgical, or psychiatric condition (including active substance abuse) that would interfere with compliance to the protocol, as determined by the Principal Investigator.
  • Female subjects of childbearing potential must agree to use dual methods of contraception and have a negative serum pregnancy test at Screening, and male subjects must use an effective barrier method of contraception if sexually active with a female of childbearing potential.
  • Subjects need a functioning, central venous access in place for the administration of agenT-797.

Exclusion Criteria:

  • Pregnant or nursing women.
  • Prior history of invasive malignancy.
  • Subjects who had an allogeneic stem cell transplantation and are still on immunosuppressive medications or corticosteroids above physiological dose.
  • New York Heart Association Class III or IV heart failure, unstable angina, or a history of recent myocardial infarction.
  • Adverse events from prior anticancer therapy that have not resolved to NCI CTCAE Grade ≤ 1.
  • Receiving any investigational products within 4 weeks or 5 half-lives of cell infusion.
View Additional Criteria

Trial Locations

All Trial Locations

View all clinical trial locations sorted by state.

Massachusetts

Dana-Farber Cancer Institute

Boston, MA

Not Yet Accepting
Interested in this trial?
  • Call us today 😀 keyboard_arrow_right

    We know how difficult and confusing this process can be. If you are interested in this clinical trial or have questions, you can call us at any time. You can also send us a direct message with questions.

    (888) 828-2206
  • If you are interested in keeping an eye on this trial, you can add it to your list of favorite trials. We'll send you alerts when this trial is updated.

  • Talk to your doctor keyboard_arrow_right

    You can print an overview of this trial to take in to your next appointment. Your doctor can help you understand if this trial may be right for you.

Still need help? Send us a message